Palivizumab Biosimilar - Research Grade

Fausther-Bovendo, H. et al. Rapid In Vivo Screening of Monoclonal Antibody Cocktails Using Hydrodynamic Delivery of DNA-Encoded Modified Antibodies. Biomedicines, 2025, 13, 637.

Human

RSV-F

5mg/ml

Human IgG1

CHO Cells

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Functional Assays

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human RSV-F. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Palivizumab.

Blue ice

The respiratory syncytial virus fusion (RSV-F) glycoprotein mediates viral entry and is the principal antigen targeted in RSV prophylaxis and vaccine research. This research-grade antibody is an unconjugated, non-therapeutic analog of palivizumab directed at the human-relevant RSV-F protein and validated for functional assays. It is offered for research use only, formulated with low endotoxin for in vivo suitability, and produced in scalable milligram to gram quantities for high-throughput laboratories. Applications include virus-neutralisation assays, fusion-protein binding studies, in vitro screening, in vivo infection models, and biologics characterisation.

ICH3002

https://www.imgt.org/mAb-DB/